Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
05 07 2023
05 07 2023
Historique:
received:
13
12
2022
accepted:
02
05
2023
medline:
6
7
2023
pubmed:
20
5
2023
entrez:
20
5
2023
Statut:
ppublish
Résumé
Cefiderocol is a catechol-substituted cephalosporin with potent in vitro activity against carbapenem-resistant (CR) Gram-negative bacteria (GNB). Cefiderocol susceptibility testing is complex because iron concentrations need to be taken into consideration. Here, we assessed the clinical performance of Bruker's UMIC® Cefiderocol and corresponding iron-depleted CAMHB to determine MIC by broth microdilution (BMD) for clinically relevant GNB. MICs of cefiderocol for 283 GN clinical isolates were determined by BMD using iron-depleted CAMHB. Frozen panels were used as a reference. The concentration range of cefiderocol was 0.03-32 mg/L. The isolates, with different degrees of susceptibility to cefiderocol, included Enterobacterales (n = 180), Pseudomonas aeruginosa (n = 49), Acinetobacter baumannii (n = 44) and Stenotrophomonas maltophilia (n = 10). The rates of categorical agreement (CA), essential agreement (EA) and bias were calculated to evaluate the performance of the UMIC® Cefiderocol, as compared with the reference method. Overall, the UMIC® Cefiderocol showed 90.8% EA (95% CI: 86.9%-93.7%) with a bias of -14.5% and a CA of 90.1% (95% CI: 86.1%-93.1%). For Enterobacterales, the UMIC® Cefiderocol showed 91.7% EA (95% CI: 86.7%-94.9%) with a bias of -25.0% and a CA of 87.8% (95% CI: 82.2%-91.8%). For non-fermenters, the UMIC® Cefiderocol showed 89.3% EA (95% CI: 81.9%-93.9%) (not significantly different from 90.0%, Student t-test) with a bias of -3.9% and a CA of 94.2% (95% CI: 87.7%-97.3%). UMIC® Cefiderocol is a valid method for the determination of cefiderocol MICs even if higher than expected discrepancies were observed with NDM-producing Enterobacterales, which presented in most cases MIC values close to the breakpoint.
Sections du résumé
BACKGROUND
Cefiderocol is a catechol-substituted cephalosporin with potent in vitro activity against carbapenem-resistant (CR) Gram-negative bacteria (GNB). Cefiderocol susceptibility testing is complex because iron concentrations need to be taken into consideration. Here, we assessed the clinical performance of Bruker's UMIC® Cefiderocol and corresponding iron-depleted CAMHB to determine MIC by broth microdilution (BMD) for clinically relevant GNB.
METHODS
MICs of cefiderocol for 283 GN clinical isolates were determined by BMD using iron-depleted CAMHB. Frozen panels were used as a reference. The concentration range of cefiderocol was 0.03-32 mg/L. The isolates, with different degrees of susceptibility to cefiderocol, included Enterobacterales (n = 180), Pseudomonas aeruginosa (n = 49), Acinetobacter baumannii (n = 44) and Stenotrophomonas maltophilia (n = 10).
RESULTS
The rates of categorical agreement (CA), essential agreement (EA) and bias were calculated to evaluate the performance of the UMIC® Cefiderocol, as compared with the reference method. Overall, the UMIC® Cefiderocol showed 90.8% EA (95% CI: 86.9%-93.7%) with a bias of -14.5% and a CA of 90.1% (95% CI: 86.1%-93.1%). For Enterobacterales, the UMIC® Cefiderocol showed 91.7% EA (95% CI: 86.7%-94.9%) with a bias of -25.0% and a CA of 87.8% (95% CI: 82.2%-91.8%). For non-fermenters, the UMIC® Cefiderocol showed 89.3% EA (95% CI: 81.9%-93.9%) (not significantly different from 90.0%, Student t-test) with a bias of -3.9% and a CA of 94.2% (95% CI: 87.7%-97.3%).
CONCLUSIONS
UMIC® Cefiderocol is a valid method for the determination of cefiderocol MICs even if higher than expected discrepancies were observed with NDM-producing Enterobacterales, which presented in most cases MIC values close to the breakpoint.
Identifiants
pubmed: 37209112
pii: 7174883
doi: 10.1093/jac/dkad149
pmc: PMC10320108
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
Iron
E1UOL152H7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1672-1676Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0199021
pubmed: 34807757
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Virulence. 2017 May 19;8(4):427-439
pubmed: 27168451
Front Microbiol. 2019 Jan 30;10:80
pubmed: 30761114
Clin Microbiol Infect. 2022 Aug;28(8):1156.e1-1156.e5
pubmed: 35533970
Diagn Microbiol Infect Dis. 2019 Aug;94(4):321-325
pubmed: 31029489
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 32727829
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 32938734
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7396-7401
pubmed: 27736756
Infect Dis Ther. 2023 Mar;12(3):777-806
pubmed: 36847998
J Antimicrob Chemother. 2019 Aug 1;74(8):2239-2246
pubmed: 31127297
Microbiol Insights. 2019 Apr 04;12:1178636119840367
pubmed: 30992668
JAC Antimicrob Resist. 2021 Jun 14;3(2):dlab081
pubmed: 34223140
BMC Microbiol. 2021 Nov 20;21(1):321
pubmed: 34798825
J Antimicrob Chemother. 2020 Sep 1;75(9):2587-2593
pubmed: 32449911
Euro Surveill. 2022 Oct;27(43):
pubmed: 36305334
Antibiotics (Basel). 2022 Oct 04;11(10):
pubmed: 36290010